Drugs / Epo
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01378273 | Dec 2013 → Feb 2019 | pulmonary immaturity | University of Washington | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01378273 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human erythropoietin (Epo)” NCT01378273 ↗ |
| Route | Intravenous | “Erythropoietin was administered intravenously at a dose of 1000 U per kilogram of body weight every 48 hours” PMID 31940698 ↗ Jan 2020 |